NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free CPRX Stock Alerts $15.62 -0.14 (-0.89%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share Today's Range$15.59▼$16.0950-Day Range$14.68▼$16.9252-Week Range$11.48▼$17.50Volume789,500 shsAverage Volume1.35 million shsMarket Capitalization$1.84 billionP/E Ratio28.93Dividend YieldN/APrice Target$26.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Catalyst Pharmaceuticals alerts: Email Address Catalyst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.0% Upside$26.71 Price TargetShort InterestBearish7.86% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.38Based on 18 Articles This WeekInsider TradingSelling Shares$2.46 M Sold Last QuarterProj. Earnings Growth21.91%From $1.78 to $2.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.76 out of 5 starsMedical Sector40th out of 903 stocksPharmaceutical Preparations Industry12th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.86% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 3.63%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 3.0 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Catalyst Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest13 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat Follows4 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,459,376.00 in company stock.Percentage Held by Insiders11.00% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 21.91% in the coming year, from $1.78 to $2.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 28.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.76.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 28.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 119.55.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 1.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Catalyst Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesJune 8 at 8:30 AM | insidertrades.comGary Ingenito Sells 80,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockJune 6, 2024 | insidertrades.comMolly Harper Sells 5,333 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockJune 8 at 8:30 AM | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Gary Ingenito Sells 80,000 Shares of StockJune 8 at 6:14 AM | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Rating Increased to Buy at StockNews.comJune 7 at 5:54 AM | americanbankingnews.comRichard J. Daly Sells 17,323 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockJune 7 at 5:14 AM | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Given "Outperform" Rating at OppenheimerJune 6, 2024 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Molly Harper Sells 5,333 SharesJune 3, 2024 | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Rating Reiterated by HC WainwrightMay 30, 2024 | globenewswire.comCatalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®May 28, 2024 | globenewswire.comCatalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024May 15, 2024 | fool.com2 Incredible Growth Stocks to Buy Hand Over Fist Right NowMay 15, 2024 | fool.com2 Incredible Growth Stocks to Buy Hand Over Fist Right NowMay 10, 2024 | markets.businessinsider.comDecoding 8 Analyst Evaluations For Catalyst PharmaceuticalsMay 8, 2024 | msn.comCPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | sfgate.comCatalyst: Q1 Earnings SnapshotMay 8, 2024 | msn.comCatalyst Pharmaceuticals Non-GAAP EPS of $0.38 beats by $0.08, revenue of $98.44M misses by $0.33MMay 8, 2024 | globenewswire.comCatalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateMay 1, 2024 | finance.yahoo.comCatalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024April 25, 2024 | globenewswire.comSanthera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in MayApril 24, 2024 | investorplace.comDirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026April 23, 2024 | barrons.comCatalyst Pharmaceuticals Inc.April 22, 2024 | globenewswire.comCatalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024April 8, 2024 | msn.comSingle Catalyst Paves the Way for Efficient Drug SynthesisApril 7, 2024 | cnn.comCatalyst Pharmaceuticals, Inc.April 6, 2024 | seekingalpha.comCatalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)See More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/09/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees167Year Founded2002Price Target and Rating Average Stock Price Target$26.71 High Stock Price Target$34.00 Low Stock Price Target$23.00 Potential Upside/Downside+71.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.54 Trailing P/E Ratio28.93 Forward P/E Ratio8.78 P/E Growth1.33Net Income$71.41 million Net Margins15.83% Pretax Margin20.98% Return on Equity25.08% Return on Assets21.26% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio4.83 Sales & Book Value Annual Sales$398.20 million Price / Sales4.63 Cash Flow$2.06 per share Price / Cash Flow7.60 Book Value$3.30 per share Price / Book4.73Miscellaneous Outstanding Shares118,110,000Free Float105,122,000Market Cap$1.84 billion OptionableOptionable Beta0.73 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Richard John Daly M.B.A. (Age 63)President, CEO & Director Comp: $68.12kDr. Steven R. Miller Ph.D. (Age 62)Executive VP, COO & Chief Scientific Officer Comp: $884.7kDr. Gary Ingenito M.D. (Age 68)Ph.D., Chief Medical & Regulatory Officer Comp: $811.39kMr. Jeffrey Del Carmen (Age 53)Executive VP & Chief Commercial Officer Comp: $799.82kMr. Michael W. Kalb CPA (Age 53)Executive VP, Treasurer & CFO Ms. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 60)Chief Compliance Officer & Chief Legal Officer Comp: $311.42kMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryDr. Preethi Sundaram Ph.D. (Age 48)Chief Strategy Officer Comp: $511.25kMore ExecutivesKey CompetitorsANI PharmaceuticalsNASDAQ:ANIPProgenics PharmaceuticalsNASDAQ:PGNXSyros PharmaceuticalsNASDAQ:SYRSCue BiopharmaNASDAQ:CUEDURECTNASDAQ:DRRXView All CompetitorsInsiders & InstitutionsGary IngenitoSold 80,000 sharesTotal: $1.29 M ($16.16/share)Richard J DalySold 17,323 sharesTotal: $276,648.31 ($15.97/share)DekaBank Deutsche GirozentraleBought 171,376 shares on 6/4/2024Ownership: 0.145%Molly HarperSold 5,333 sharesTotal: $86,927.90 ($16.30/share)Opaleye Management Inc.Sold 252,845 shares on 5/29/2024Ownership: 0.850%View All Insider TransactionsView All Institutional Transactions CPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price target for 2024? 5 Wall Street analysts have issued 12 month target prices for Catalyst Pharmaceuticals' shares. Their CPRX share price targets range from $23.00 to $34.00. On average, they predict the company's stock price to reach $26.71 in the next twelve months. This suggests a possible upside of 71.0% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2024? Catalyst Pharmaceuticals' stock was trading at $16.81 on January 1st, 2024. Since then, CPRX shares have decreased by 7.1% and is now trading at $15.62. View the best growth stocks for 2024 here. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.31. The biopharmaceutical company earned $98.51 million during the quarter, compared to analyst estimates of $97.24 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 25.08% and a net margin of 15.83%. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 GARP ETF (GRPZ), ALPS Medical Breakthroughs ETF (SBIO) and ERShares NextGen Entrepreneurs ETF (ERSX). What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $460.5 million. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.76%), Janus Henderson Group PLC (2.31%), Boston Partners (1.28%), Jacobs Levy Equity Management Inc. (1.06%), Price T Rowe Associates Inc. MD (1.03%) and Kennedy Capital Management LLC (0.90%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Molly Harper, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram, Richard J Daly and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CPRX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.